
The project has been extended by six months (to June 2022) to overcome some of the challenges posed by the COVID-19 pandemic. This will enable the team to complete our ambitious work on tracking therapeutic cells and cell products in arthritis models.
We are now looking ahead and thinking about how best to build on our success with a follow-up project.